DexCom, Inc. $DXCM Shares Sold by Greenup Street Wealth Management LLC

Greenup Street Wealth Management LLC lessened its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 50.2% in the 1st quarter, Holdings Channel reports. The institutional investor owned 16,968 shares of the medical device company’s stock after selling 17,075 shares during the quarter. Greenup Street Wealth Management LLC’s holdings in DexCom were worth $1,066,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the stock. Norges Bank purchased a new position in shares of DexCom in the 4th quarter valued at $483,356,000. AQR Capital Management LLC lifted its position in DexCom by 597.8% in the fourth quarter. AQR Capital Management LLC now owns 3,102,789 shares of the medical device company’s stock valued at $205,932,000 after acquiring an additional 2,658,158 shares during the last quarter. Holocene Advisors LP purchased a new stake in DexCom in the third quarter valued at $163,964,000. CIBC Private Wealth Group LLC lifted its position in DexCom by 374.3% in the third quarter. CIBC Private Wealth Group LLC now owns 2,907,801 shares of the medical device company’s stock valued at $195,666,000 after acquiring an additional 2,294,709 shares during the last quarter. Finally, Employees Provident Fund Board acquired a new position in DexCom in the fourth quarter valued at $145,352,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Stock Performance

NASDAQ:DXCM opened at $69.73 on Thursday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64. The firm has a market cap of $26.91 billion, a price-to-earnings ratio of 29.80, a price-to-earnings-growth ratio of 1.08 and a beta of 1.45. The firm’s fifty day moving average price is $67.36 and its 200 day moving average price is $68.04. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $89.98.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The company had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter in the prior year, the firm earned $0.32 EPS. DexCom’s quarterly revenue was up 15.0% on a year-over-year basis. On average, sell-side analysts expect that DexCom, Inc. will post 2.58 EPS for the current year.

Insider Buying and Selling at DexCom

In related news, EVP Jon Coleman sold 4,912 shares of the firm’s stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $73.00, for a total value of $358,576.00. Following the completion of the sale, the executive vice president owned 100,361 shares in the company, valued at $7,326,353. This trade represents a 4.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,759 shares of DexCom stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $72.00, for a total value of $1,926,648.00. Following the completion of the sale, the insider directly owned 382,482 shares in the company, valued at $27,538,704. This represents a 6.54% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 46,694 shares of company stock valued at $3,343,977. Insiders own 0.28% of the company’s stock.

Analyst Ratings Changes

DXCM has been the topic of several research reports. TD Cowen reaffirmed a “buy” rating and set a $95.00 price objective (up from $75.00) on shares of DexCom in a report on Wednesday, June 10th. Deutsche Bank Aktiengesellschaft initiated coverage on DexCom in a report on Tuesday. They issued a “buy” rating and a $86.00 target price for the company. BTIG Research reissued a “buy” rating and issued a $85.00 target price on shares of DexCom in a research report on Monday, March 9th. Sanford C. Bernstein set a $77.00 price target on DexCom in a research note on Friday, May 1st. Finally, Mizuho set a $85.00 price target on DexCom and gave the stock an “outperform” rating in a research report on Tuesday, June 9th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, DexCom currently has a consensus rating of “Moderate Buy” and a consensus price target of $84.88.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.